Imaging HER2-low breast cancers using a specialized PET scan
HER2-PET Imaging Using 89Zr-trastuzumab in Low HER2-expressing (HER2-low) Breast Cancers
PHASE1; PHASE2 · Centre de recherche du Centre hospitalier universitaire de Sherbrooke · NCT06732336
This study is testing a new type of PET scan that uses a special version of a breast cancer drug to see if it can better find HER2-low breast cancers that might have been missed before.
Quick facts
| Phase | PHASE1; PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre de recherche du Centre hospitalier universitaire de Sherbrooke (other) |
| Drugs / interventions | trastuzumab, immunotherapy, pertuzumab, chemotherapy |
| Locations | 1 site (Sherbrooke, Quebec) |
| Trial ID | NCT06732336 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the diagnostic potential of a new imaging technique that utilizes a radiolabeled version of the anti-HER2 antibody trastuzumab to detect HER2-low expressing breast cancers. The approach combines this imaging with existing FDG PET scans to improve the identification of metastatic breast cancer cases that may have previously been classified as HER2-negative. By focusing on HER2-low status, which has gained relevance due to recent advancements in immunotherapy, the study seeks to enhance the accuracy of cancer detection and treatment planning. Participants will undergo PET imaging with 89Zr-trastuzumab to assess its effectiveness in identifying these cancers.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with HER2-low metastatic breast cancer.
Not a fit: Patients who are pregnant, breastfeeding, or have significant hepatic or renal disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy for patients with HER2-low breast cancers, potentially guiding more effective treatment options.
How similar studies have performed: Other studies have shown promise in targeting HER2+ lesions with similar imaging techniques, indicating a potential for success in this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * HER2-low metastatic breast cancer; * At least 18 years-old ; * Able to stay in supine position for at least 30 minutes; * Written inform consent. Exclusion Criteria: * Pregnancy or concomitant breast feeding; * Hepatic disorders such as cirrhosis, hepatitis, or any other liver condition judged as significant by the treating physician and that could impair the biliary excretion of 89Zr-trastuzumab; * Renal disorders considered significant by the treating physician and that could impair the normal elimination of 89Zr-trastuzumab; * Known hypersensitivity or allergy to trastuzumab, desferrioxamine, or any constituents of 89Zr-trastuzumab.
Where this trial is running
Sherbrooke, Quebec
- Centre de recherche du CHUS — Sherbrooke, Quebec, Canada (RECRUITING)
Study contacts
- Principal investigator: Éric E Turcotte, MD, FRCPC — Université de Sherbrooke
- Study coordinator: Michel Paquette, PhD
- Email: michel.paquette@usherbrooke.ca
- Phone: 819-346-1110
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Breast Cancer Metastatic, HER2, HER2-low, PET, Breast cancer, 89Zr-trastuzumab